257 related articles for article (PubMed ID: 29396094)
1. R-CHOP, radioimmunotherapy, and maintenance rituximab in untreated follicular lymphoma (SWOG S0801): a single-arm, phase 2, multicentre study.
Barr PM; Li H; Burack WR; LeBlanc M; Smith SM; Gopal AK; Floyd JD; Persky DO; Press OW; Fisher RI; Friedberg JW
Lancet Haematol; 2018 Mar; 5(3):e102-e108. PubMed ID: 29396094
[TBL] [Abstract][Full Text] [Related]
2. Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016.
Press OW; Unger JM; Rimsza LM; Friedberg JW; LeBlanc M; Czuczman MS; Kaminski M; Braziel RM; Spier C; Gopal AK; Maloney DG; Cheson BD; Dakhil SR; Miller TP; Fisher RI
J Clin Oncol; 2013 Jan; 31(3):314-20. PubMed ID: 23233710
[TBL] [Abstract][Full Text] [Related]
3. Outcomes after R-CHOP in patients with newly diagnosed advanced follicular lymphoma: a 10-year follow-up analysis of the JCOG0203 trial.
Watanabe T; Tobinai K; Wakabayashi M; Morishima Y; Kobayashi H; Kinoshita T; Suzuki T; Yamaguchi M; Ando K; Ogura M; Taniwaki M; Uike N; Yoshino T; Nawano S; Terauchi T; Hotta T; Nagai H; Tsukasaki K;
Lancet Haematol; 2018 Nov; 5(11):e520-e531. PubMed ID: 30389034
[TBL] [Abstract][Full Text] [Related]
4. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study.
Robak T; Jin J; Pylypenko H; Verhoef G; Siritanaratkul N; Drach J; Raderer M; Mayer J; Pereira J; Tumyan G; Okamoto R; Nakahara S; Hu P; Appiani C; Nemat S; Cavalli F;
Lancet Oncol; 2018 Nov; 19(11):1449-1458. PubMed ID: 30348538
[TBL] [Abstract][Full Text] [Related]
5. Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus
Shadman M; Li H; Rimsza L; Leonard JP; Kaminski MS; Braziel RM; Spier CM; Gopal AK; Maloney DG; Cheson BD; Dakhil S; LeBlanc M; Smith SM; Fisher RI; Friedberg JW; Press OW
J Clin Oncol; 2018 Mar; 36(7):697-703. PubMed ID: 29356608
[TBL] [Abstract][Full Text] [Related]
6. R-CHOP with iodine-131 tositumomab consolidation for advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0433.
Friedberg JW; Unger JM; Burack WR; Gopal AK; Raju RN; Nademanee AP; Kaminski MS; Li H; Press OW; Miller TP; Fisher RI
Br J Haematol; 2014 Aug; 166(3):382-9. PubMed ID: 24749780
[TBL] [Abstract][Full Text] [Related]
7. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
[TBL] [Abstract][Full Text] [Related]
8. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
[TBL] [Abstract][Full Text] [Related]
9. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial.
Poeschel V; Held G; Ziepert M; Witzens-Harig M; Holte H; Thurner L; Borchmann P; Viardot A; Soekler M; Keller U; Schmidt C; Truemper L; Mahlberg R; Marks R; Hoeffkes HG; Metzner B; Dierlamm J; Frickhofen N; Haenel M; Neubauer A; Kneba M; Merli F; Tucci A; de Nully Brown P; Federico M; Lengfelder E; di Rocco A; Trappe R; Rosenwald A; Berdel C; Maisenhoelder M; Shpilberg O; Amam J; Christofyllakis K; Hartmann F; Murawski N; Stilgenbauer S; Nickelsen M; Wulf G; Glass B; Schmitz N; Altmann B; Loeffler M; Pfreundschuh M; ;
Lancet; 2019 Dec; 394(10216):2271-2281. PubMed ID: 31868632
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial.
Trotman J; Barrington SF; Belada D; Meignan M; MacEwan R; Owen C; Ptáčník V; Rosta A; Fingerle-Rowson GR; Zhu J; Nielsen T; Sahin D; Hiddemann W; Marcus RE; Davies A;
Lancet Oncol; 2018 Nov; 19(11):1530-1542. PubMed ID: 30309758
[TBL] [Abstract][Full Text] [Related]
11. Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial.
Davies A; Cummin TE; Barrans S; Maishman T; Mamot C; Novak U; Caddy J; Stanton L; Kazmi-Stokes S; McMillan A; Fields P; Pocock C; Collins GP; Stephens R; Cucco F; Clipson A; Sha C; Tooze R; Care MA; Griffiths G; Du MQ; Westhead DR; Burton C; Johnson PWM
Lancet Oncol; 2019 May; 20(5):649-662. PubMed ID: 30948276
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of rituximab in patients with diffuse large B-cell lymphoma in Malawi: a prospective, single-arm, non-randomised phase 1/2 clinical trial.
Kimani S; Painschab MS; Kaimila B; Kasonkanji E; Zuze T; Tomoka T; Mulenga M; Nyasosela R; Chikasema M; Mtangwanika A; Chawinga M; Mhango W; Nicholas S; Chimzimu F; Kampani C; Krysiak R; Lilly A; Randall C; Seguin R; Westmoreland KD; Montgomery ND; Fedoriw Y; Gopal S
Lancet Glob Health; 2021 Jul; 9(7):e1008-e1016. PubMed ID: 34022150
[TBL] [Abstract][Full Text] [Related]
13. Consolidation anti-CD22 fractionated radioimmunotherapy with
Kraeber-Bodere F; Pallardy A; Maisonneuve H; Campion L; Moreau A; Soubeyran I; Le Gouill S; Tournilhac O; Daguindau E; Jardel H; Morineau N; Bouabdallah K; Gyan E; Moles MP; Gressin R; Berthou C; Sadot S; Moreau P; Deau B; Bodet-Milin C; Cazeau AL; Garin E; Salaun PY; Vuillez JP; Gouilleux-Gruart V; Barbet J; Wegener WA; Goldenberg DM; Lamy T; Soubeyran P
Lancet Haematol; 2017 Jan; 4(1):e35-e45. PubMed ID: 27964867
[TBL] [Abstract][Full Text] [Related]
14. Lenalidomide in combination with R-CHOP (R2-CHOP) as first-line treatment of patients with high tumour burden follicular lymphoma: a single-arm, open-label, phase 2 study.
Tilly H; Morschhauser F; Casasnovas O; Molina TJ; Feugier P; Gouill SL; Haioun C; Tournilhac O; Bouabdallah R; Gabarre J; Lamy T; Cabeçadas J; Becker S; Jardin F; Mounier N; Salles G;
Lancet Haematol; 2018 Sep; 5(9):e403-e410. PubMed ID: 30172345
[TBL] [Abstract][Full Text] [Related]
15. Treatment of older patients with mantle-cell lymphoma.
Kluin-Nelemans HC; Hoster E; Hermine O; Walewski J; Trneny M; Geisler CH; Stilgenbauer S; Thieblemont C; Vehling-Kaiser U; Doorduijn JK; Coiffier B; Forstpointner R; Tilly H; Kanz L; Feugier P; Szymczyk M; Hallek M; Kremers S; Lepeu G; Sanhes L; Zijlstra JM; Bouabdallah R; Lugtenburg PJ; Macro M; Pfreundschuh M; Procházka V; Di Raimondo F; Ribrag V; Uppenkamp M; André M; Klapper W; Hiddemann W; Unterhalt M; Dreyling MH
N Engl J Med; 2012 Aug; 367(6):520-31. PubMed ID: 22873532
[TBL] [Abstract][Full Text] [Related]
16. Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trial.
Ladetto M; Cortelazzo S; Ferrero S; Evangelista A; Mian M; Tavarozzi R; Zanni M; Cavallo F; Di Rocco A; Stefoni V; Pagani C; Re A; Chiappella A; Balzarotti M; Zilioli VR; Gomes da Silva M; Arcaini L; Molinari AL; Ballerini F; Ferreri AJM; Puccini B; Benedetti F; Stefani PM; Narni F; Casaroli I; Stelitano C; Ciccone G; Vitolo U; Martelli M
Lancet Haematol; 2021 Jan; 8(1):e34-e44. PubMed ID: 33357480
[TBL] [Abstract][Full Text] [Related]
17. Short duration immunochemotherapy followed by radioimmunotherapy consolidation is effective and well tolerated in relapsed follicular lymphoma: 5-year results from a UK National Cancer Research Institute Lymphoma Group study.
Illidge TM; McKenzie HS; Mayes S; Bates A; Davies AJ; Pettengell R; Stanton L; Cozens K; Hampson G; Dive C; Zivanovic M; Tipping J; Gallop-Evans E; Radford JA; Johnson PW
Br J Haematol; 2016 Apr; 173(2):274-82. PubMed ID: 26849853
[TBL] [Abstract][Full Text] [Related]
18. First-line R-CVP versus R-CHOP induction immunochemotherapy for indolent lymphoma with rituximab maintenance. A multicentre, phase III randomized study by the Polish Lymphoma Research Group PLRG4.
Walewski J; Paszkiewicz-Kozik E; Michalski W; Rymkiewicz G; Szpila T; Butrym A; Giza A; Zaucha JM; Kalinka-Warzocha E; Wieczorkiewicz A; Zimowska-Curyło D; Knopińska-Posłuszny W; Tyczyńska A; Romejko-Jarosińska J; Dąbrowska-Iwanicka A; Gruszecka B; Jamrozek-Jedlińska M; Borawska A; Hołda W; Porowska A; Romanowicz A; Hellmann A; Stella-Hołowiecka B; Deptała A; Jurczak W
Br J Haematol; 2020 Mar; 188(6):898-906. PubMed ID: 31792945
[TBL] [Abstract][Full Text] [Related]
19. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
Cunningham D; Hawkes EA; Jack A; Qian W; Smith P; Mouncey P; Pocock C; Ardeshna KM; Radford JA; McMillan A; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D
Lancet; 2013 May; 381(9880):1817-26. PubMed ID: 23615461
[TBL] [Abstract][Full Text] [Related]
20. Positron Emission Tomography-Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001.
Persky DO; Li H; Stephens DM; Park SI; Bartlett NL; Swinnen LJ; Barr PM; Winegarden JD; Constine LS; Fitzgerald TJ; Leonard JP; Kahl BS; LeBlanc ML; Song JY; Fisher RI; Rimsza LM; Smith SM; Miller TP; Friedberg JW
J Clin Oncol; 2020 Sep; 38(26):3003-3011. PubMed ID: 32658627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
